-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
LumiraDx (NASDAQ:LMDX) Receives New Coverage From Analysts at The Goldman Sachs Group
LumiraDx (NASDAQ:LMDX) Receives New Coverage From Analysts at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research note released on Monday morning, The Fly reports. The firm issued a neutral rating on the stock.
Separately, Raymond James decreased their price target on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research report on Friday, November 11th.
Get LumiraDx alerts:LumiraDx Stock Performance
NASDAQ LMDX opened at $0.96 on Monday. The company has a debt-to-equity ratio of 20.12, a current ratio of 2.91 and a quick ratio of 1.63. The firm has a market capitalization of $43.43 million, a price-to-earnings ratio of -0.68 and a beta of 1.05. The company's fifty day moving average is $1.09 and its two-hundred day moving average is $1.66. LumiraDx has a 52-week low of $0.77 and a 52-week high of $10.42.
Institutional Trading of LumiraDx
Several institutional investors have recently made changes to their positions in LMDX. Bill & Melinda Gates Foundation acquired a new stake in shares of LumiraDx during the 3rd quarter valued at about $14,600,000. Senvest Management LLC lifted its holdings in LumiraDx by 297.0% during the 3rd quarter. Senvest Management LLC now owns 10,737,651 shares of the company's stock valued at $10,952,000 after purchasing an additional 8,032,616 shares during the last quarter. Balyasny Asset Management LLC lifted its holdings in LumiraDx by 36,072.9% during the 3rd quarter. Balyasny Asset Management LLC now owns 3,771,385 shares of the company's stock valued at $3,847,000 after purchasing an additional 3,760,959 shares during the last quarter. Pictet Asset Management SA bought a new position in LumiraDx during the 3rd quarter valued at about $1,659,000. Finally, Colony Group LLC bought a new position in LumiraDx during the 2nd quarter valued at about $787,000.LumiraDx Company Profile
(Get Rating)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
See Also
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
The Goldman Sachs Group started coverage on shares of LumiraDx (NASDAQ:LMDX – Get Rating) in a research note released on Monday morning, The Fly reports. The firm issued a neutral rating on the stock.
據The Fly報道，高盛在週一上午發佈的一份研究報告中開始對LumiraDx(納斯達克代碼：lmdx-Get Rating)的股票進行報道。該公司對該股的評級為中性。
Separately, Raymond James decreased their price target on shares of LumiraDx from $4.00 to $3.50 and set an outperform rating on the stock in a research report on Friday, November 11th.
另外，Raymond James在11月11日星期五的一份研究報告中將LumiraDx的目標價從4.00美元下調至3.50美元，並對該股設定了表現優於大盤的評級。
LumiraDx Stock Performance
LumiraDx股票表現
NASDAQ LMDX opened at $0.96 on Monday. The company has a debt-to-equity ratio of 20.12, a current ratio of 2.91 and a quick ratio of 1.63. The firm has a market capitalization of $43.43 million, a price-to-earnings ratio of -0.68 and a beta of 1.05. The company's fifty day moving average is $1.09 and its two-hundred day moving average is $1.66. LumiraDx has a 52-week low of $0.77 and a 52-week high of $10.42.
納斯達克LMDX週一開盤價為0.96美元。該公司的債務權益比為20.12，流動比率為2.91，速動比率為1.63。該公司市值為4,343萬美元，本益比為-0.68倍，貝塔係數為1.05。該公司的50日移動均線切入位在1.09美元，200日移動均線切入位在1.66美元。LumiraDx的52周低點為0.77美元，52周高點為10.42美元。
Institutional Trading of LumiraDx
LumiraDx的機構交易
LumiraDx Company Profile
LumiraDx公司簡介
(Get Rating)
(獲取評級)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
LumiraDx有限公司是一家醫療診斷公司。該公司專注於通過向醫療保健提供者提供關鍵診斷資訊來轉變基於社區的醫療保健。它製造和銷售一種診斷平臺，該平臺支持各種測試，在護理點具有實驗室可比的性能。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on LumiraDx (LMDX)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 免費獲取StockNews.com在LumiraDx(LMDX)上的研究報告
- 如果馬斯克退出Twitter，特斯拉的股價會上漲嗎？
- 2023年值得關注的5個下跌但不是下跌的股票
- Chewy能否在2023年獲得兩位數的增長？
- 禮來公司預計將實現持久增長，儘管面臨眼前的挑戰
- Madrigal製藥公司的股票在一天內上漲了200%，原因如下
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.
接收LumiraDx日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對LumiraDx和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧